CA - Crescita Therapeutics announces approval of normal course issuer bid
2023-08-29 08:03:21 ET
- Crescita Therapeutics ( OTCPK:CRRTF ) Tuesday announced that the Toronto Stock Exchange has approved the company’s proposed normal course issuer bid to purchase up to a maximum of 1,821,616 common shares for cancellation, representing about 10% of its public float as of August 18, as appropriate opportunities arise from time to time.
- As of August 27, 2023, the company had 20,374,153 issued and outstanding common shares.
- Purchases under the NCIB will be made through the facilities of the TSX or through a Canadian alternative trading system and in accordance with applicable regulatory requirements at a price per common share representative of the market price at the time of acquisition.
- The company may begin to purchase shares on August 31, 2023 and the NCIB will terminate on August 30, 2024 or such earlier time as the company completes its purchases pursuant to the NCIB or provides notice of termination.
- Source: Press Release
For further details see:
Crescita Therapeutics announces approval of normal course issuer bid